NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis $1.39 +0.02 (+1.46%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 10/15/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Enveric Biosciences Stock (NASDAQ:ENVB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enveric Biosciences alerts:Sign Up Key Stats Today's Range$1.35▼$1.4450-Day Range$1.31▼$1.6252-Week Range$1.17▼$13.25Volume20,554 shsAverage Volume81,772 shsMarket Capitalization$6.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapeutics for cancer and central nervous system disorders. The company’s research programs draw on cannabinoid- and psychedelic-inspired compounds intended to address unmet medical needs while potentially avoiding some of the limitations associated with naturally occurring compounds. Enveric has developed a pipeline of investigational small-molecule drug candidates, including programs aimed at neuropsychiatric conditions such as depression and cancer-related complications. Its research platform has included the Psybrary library of novel psychedelic molecules, which was obtained through the company’s acquisition of Canadian biotechnology company MagicMed Industries. Enveric has also pursued oncology programs involving cannabinoid-derived compounds and treatments for symptoms associated with cancer and its therapies. Headquartered in Naples, Florida, Enveric Biosciences conducts drug discovery and development activities for potential use in major international healthcare markets. Its candidates remain investigational and are subject to clinical and regulatory evaluation; the company does not currently market approved therapies based on these programs.AI Generated. May Contain Errors. Read More Enveric Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreENVB MarketRank™: 1.1200105042 of 5 starsEnveric Biosciences scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnveric Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enveric Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.35% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 32.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentEnveric Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.41% of the stock of Enveric Biosciences is held by insiders.Percentage Held by Institutions13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENVB Stock News HeadlinesEnveric Biosciences Inc ENVBSeptember 16, 2026 | morningstar.comMEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesSeptember 15, 2026 | finance.yahoo.comMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. | Porter & Company (Ad)Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesSeptember 15, 2026 | businesswire.comEnveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026August 14, 2026 | businesswire.comEnveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric CandidateAugust 5, 2026 | benzinga.comEnveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug DevelopmentJuly 28, 2026 | finance.yahoo.comEnveric Biosciences Announces Participation in 2026 BIO International ConventionJune 16, 2026 | businesswire.comSee More Headlines ENVB Stock Analysis - Frequently Asked Questions How have ENVB shares performed this year? Enveric Biosciences' stock was trading at $3.63 at the beginning of 2026. Since then, ENVB shares have decreased by 61.7% and is now trading at $1.39. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) released its earnings results on Friday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter. When did Enveric Biosciences' stock split? Enveric Biosciences shares reverse split before market open on Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enveric Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), MARA (MARA), Tesla (TSLA), AMC Entertainment (AMC), IonQ (IONQ) and SoundHound AI (SOUN). Company Calendar Last Earnings8/14/2026Today10/15/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ENVB's financial health is in the Yellow zone, according to TradeSmith. ENVB has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENVB CIK890821 Webwww.enveric.com Phone(617) 444-8400Fax732-243-9254Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($12.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-168.04% Return on Assets-145.95% Debt Debt-to-Equity RatioN/A Current Ratio10.21 Quick Ratio10.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.00 per share Price / Book0.20Miscellaneous Outstanding Shares4,480,000Free Float4,368,000Market Cap$6.23 million OptionableNot Optionable Beta1.18 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ENVB) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
